ANA Therapeutics
Founded in response to the COVID-19 pandemic, we’re investigating niclosamide as a treatment for COVID-19.
Employees
Enterprise value
$20—30m
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
Jack Abraham(exited)
Paul Buchheit(exited)
Matt Rogers(exited)
Swati Mylavarapu(exited)
Neal Khosla(exited)
Refactor Capital(exited)
SV Tech Ventures(exited)
SV Angel(exited)
SOSV(exited)
Sam Altman(exited)
Blue Bear Ventures(exited)
Realm Capital Ventures(exited)
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.